Novo Nordisk Launches Oral Wegovy Pill in US Amid Competitive Market

Novo Nordisk has introduced its oral Wegovy pill in the United States, offering a needle-free alternative to injectable weight-loss treatments. Priced between $149 and $299 per month, the pill aims to capture cash-paying consumers in a competitive market dominated by Eli Lilly's Zepbound.

Insights:
Novo Nordisk A/S has launched its once-daily oral Wegovy pill in the United States on January 6, 2025, following the U.S. Food and Drug Administration's approval in December 2024. This strategic move aims to provide a needle-free alternative to injectable weight-loss treatments, addressing the company's profit warnings and declining share prices in 2025. The pill, priced between $149 and $299 per month depending on dosage, targets cash-paying consumers who lack insurance coverage.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little